Risk Minimisation Materials

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

This brochure provides important advice on the management of potential renal and bone effects of Tenofovir disoproxil in adolescent patients with chronic hepatitis B aged 12 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals